AstraZeneca, Merck go multilingual for prostate cancer push

It’s not unusual for campaigns that are featured in Campaign Confidential to have a specific target audience.

Often in this space, there’s coverage of rare disease educational efforts that ultimately focus on a patient community of a few hundred or thousand patients in the U.S.

Conversely, some campaigns go for a broader audience registering in the millions.

The Never Miss campaign from AstraZeneca and Merck (MSD) is in the latter camp.